Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  cancer  company  mar  march  marketwired mar  marketwired march  marketwired  new  shares  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Wed, 29 Mar 2017 08:21:55 EDT

Copyright: Copyright: (C) Marketwired
 



DiamiR Announces Oral Presentation at AD/PD(TM) 2017

Wed, 29 Mar 2017 08:02:00 EDT

MONMOUTH JUNCTION, NJ--(Marketwired - March 29, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Samuil Umansky, MD, PhD, Chief Scientific Officer, will be presenting at The 13th International Conference on Alzheimer's & Parkinson's Diseases (AD/PDT 2017) being held March 29 - April 2, 2017 in Vienna, Austria.




Revive Therapeutics Provides Corporate Update

Wed, 29 Mar 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today provided a corporate update on its Phase 2 clinical study of REV-004 (Bucillamine) in cystinuria and warrant exercise.




Trillium Therapeutics to Present at Investor and Scientific Conferences in April

Wed, 29 Mar 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.




Genetic Technologies and IndyCar's Pippa Mann Partner for Second Consecutive Year to Promote BREVAGenplus(R)

Wed, 29 Mar 2017 05:30:00 EDT

MELBOURNE, AUSTRALIA--(Marketwired - Mar 29, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company focused on cancer risk assessment, announced today an agreement with Dale Coyne Racing driver Ms. Pippa Mann to promote BREVAGenplus®, the Company's first-in-class, clinically validated risk assessment test for sporadic breast cancer. The partnership is reflective of the Company's continuation of its U.S. focused marketing program for BREVAGenplus, with Mann serving for a second consecutive term as the product's ambassador and spokesperson. Mann is one of only nine female athletes to ever compete in the "Indy 500" and the only female driver to start in the race over the past four consecutive years. In addition to her role with Genetic Technologies, Mann is partnering with Susan G. Komen®, the world's largest breast cancer organisation, which funds more breast cancer research than any other non-profit, outside of the U.S. government, while providing screening, education, treatment and psychosocial support programs. In 2016, Mann was honoured as one of Komen's More Than PinkT heroes in support of the organisations Bold Goal - to reduce the current number of breast cancer deaths in the U.S. by half, by 2026. 




Atossa Genetics, Inc. Prices $4,000,000 Public Offering

Wed, 29 Mar 2017 01:50:25 EDT

SEATTLE, WA--(Marketwired - Mar 29, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering with anticipated gross proceeds of $4,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering consists of (i) Class A Units consisting of 664,000 shares of our Common Stock and Warrants to purchase 664,000 shares of Common Stock, and (ii) Class B Units consisting of 3,502 shares of our Series A Convertible Preferred Stock, with a face value of $1,000 and each convertible into 1,333.33 shares of Common Stock, and Warrants exercisable for the number of shares of Common Stock into which the shares of Series A Convertible Preferred Stock are convertible. The Warrants will have an exercise price of $0.9375, will be exercisable upon issuance and will expire five years from the date of issuance. Atossa has granted the underwriters a 45-day option to purchase up to an additional 800,000 shares of Common Stock and/or 800,000 Warrants to cover over-allotments, if any. The offering is expected to close on April 3, 2017, subject to customary closing conditions.




Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial

Tue, 28 Mar 2017 18:28:22 EDT

LOS ANGELES, CA--(Marketwired - Mar 28, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR)




IntelGenx Reports Fourth Quarter and Full-Year 2016 Financial Results

Tue, 28 Mar 2017 16:01:00 EDT

SAINT LAURENT, QUEBEC--(Marketwired - March 28, 2017) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2016. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.




Medtronic, DePuy Synthes Lead Cervical and Lumbar Artificial Disc Market Due to Positive Clinical Results and Emerging Technologies

Tue, 28 Mar 2017 12:27:58 EDT

Overall, the U.S. spinal implants and vertebral compression fracture market is expected to increase and reach nearly $7 billion by 2023




LogixHealth Publishes ED Facility-Focused Intelligence Briefing: 2017 Emergency Department Outpatient Payment System Update

Tue, 28 Mar 2017 12:00:00 EDT

BEDFORD, MA--(Marketwired - Mar 28, 2017) - LogixHealth, a leading provider of internet and software enabled coding, billing, analytics and management services for hospital and physician practices nationwide, provides services for millions of Emergency Department (ED) visits nationwide, and has published its newest facility-focused intelligence briefing: 2017 Emergency Department Outpatient Payment System Update. On November 1, 2016, CMS published the 2017 Outpatient Prospective Payment System (OPPS) final rule in the Federal Register, which finalizes payment rates and policies for outpatient services furnished by hospitals that are paid under the OPPS, and governs services provided on or after January 1, 2017. The rule, and the full 2017 Emergency Department Outpatient Payment System Update can be found on the LogixHealth website.




NSAV Announces Cancellation of 3.0 Billion KBM Worldwide Shares

Tue, 28 Mar 2017 10:22:38 EDT

CRESCO, PA--(Marketwired - Mar 28, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has cancelled 3.0 billion shares of its common stock that had been pledged to KBM Worldwide in a settlement negotiated by the Company's previous management. The Company took this action as these shares were part of an agreement between NSAV and its former management and China Food and Beverage Company (OTC: CHIF). The agreement expired on June 30, 2016 and is now null and void. The Company feels that this action is in the best interest of NSAV and its shareholders.




Propanc Receives Patentability Opinion for Method of Treating Cancer Stem Cells

Tue, 28 Mar 2017 08:30:00 EDT

International Search Report concludes majority of claims are novel and inventive




ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team

Tue, 28 Mar 2017 08:05:00 EDT

Company Names New Board Member, Continues to Build Out Operations Team Through Appointment and Promotions




Oral Film Exclusivity Granted to IntelGenx' VersaFilm(TM) for Tadalafil Erectile Dysfunction Dosing Patent

Tue, 28 Mar 2017 08:00:00 EDT

SAINT LAURENT, QUEBEC--(Marketwired - March 28, 2017) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today announced that Eli Lilly and Company granted IntelGenx' VersaFilmT an exclusive license for tadalafil film product under erectile dysfunction (ED) dosing patent, United States Patent No. 6,943,166 (the '166 dosing patent). Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.




Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

Tue, 28 Mar 2017 07:30:00 EDT

VALENCIA, SPAIN--(Marketwired - Mar 28, 2017) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our joint venture based at Sci-Tech, Daresbury (UK), has engaged Future Diagnostics Solutions B.V. ("Future Diagnostics") for assay development services.




Surveyed Top 50 Pharma and Biotech Companies Report Average Per-Patient Costs of $57,500 During Non-Adaptive Phase 1 Studies

Mon, 27 Mar 2017 19:28:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - March 27, 2017) - Surveyed pharmaceutical, biotech, and device companies expend up to $120,000 per patient during Phase 1 non-adaptive studies, according to recent data published by business intelligence firm Cutting Edge Information. Comparing survey responses for Phase 1 adaptive design clinical trials shows that companies typically expect to spend no more than $80,000 per patient.




CBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017

Mon, 27 Mar 2017 15:40:40 EDT

CBIS Sets the Stage to Meet the Increasing Consumer Demand With Even More Medicinal Products for its Nationwide Observational and Clinical Studies




Ogilvy CommonHealth Worldwide and InTouchMD Announce Partnership

Mon, 27 Mar 2017 09:33:39 EDT

PARSIPPANY, NJ--(Marketwired - Mar 27, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com) and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced the creation of a formal partnership with InTouchMD (www.intouchmd.com), a leading healthcare marketing and solutions company.




BioStem Technologies, Inc. Announces Issuance of Prescription Drug Repackager Permit for Qualified Pharma Ingredients Inc.

Mon, 27 Mar 2017 09:30:00 EDT

POMPANO BEACH, FL--(Marketwired - Mar 27, 2017) -  BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International Biotechnology company, is eager to announce that its Oakland Park, Florida-based subsidiary, Qualified Pharma Ingredients Inc. ("QPI"), has been granted their Prescription Drug Repackager permit from the Florida Department of Business & Professional Regulation.




Sprint CEO Marcelo Claure to Keynote at PegaWorld 2017

Mon, 27 Mar 2017 09:00:00 EDT

Pegasystems' annual conference to explore how technology can empower organizations to achieve new levels of performance and make change a competitive advantage




GeoVax Reports on Vaccine Development Progress

Mon, 27 Mar 2017 09:00:00 EDT

Expanding Pipeline for MVA-VLP Vaccine Platform Includes HIV, Zika, Ebola, Malaria, Hepatitis B and Cancer




Advantis Corp. Expands Product and Distribution Channels

Mon, 27 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 27, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is partnering with a new cooperative group that is licensed to operate in San Diego. The cooperative, who will be carrying various expanded Advantis product lines, is a technology based delivery service that delivers medical marijuana to its members anywhere in the city within two hours.




VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi

Mon, 27 Mar 2017 08:30:00 EDT

VIVUS to Receive Commercial Rights to Africa, the Middle East, Turkey and the Commonwealth of Independent States, Including Russia




BriaCell Closes CEO Equity Investment

Fri, 24 Mar 2017 18:22:47 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,346,900 with its President and CEO, Dr. William Williams.




BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory

Fri, 24 Mar 2017 14:18:03 EDT

OAKLAND PARK, FL--(Marketwired - Mar 24, 2017) -  BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM's Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b regulations, which caused an extension to our timeline, but I couldn't be prouder of this new state-of-the-art facility. Cutting the ribbon with Mayor Lamar Fisher (City of Pompano Beach) was a very proud moment for the entire BSEM team, and it is a testament to how far we have come since the Company's inception in 2014."




Kessler Foundation Renews Collaboration with Children's Specialized Hospital

Fri, 24 Mar 2017 14:08:11 EDT

EAST HANOVER, NJ and NEW BRUNSWICK, NJ--(Marketwired - March 24, 2017) - Kessler Foundation, a global leader in rehabilitation research, and Children's Specialized Hospital, the nation's leading provider of inpatient and outpatient care for children facing special health challenges, have renewed their collaboration by signing a three-year agreement, with a funding level of $2.1 million, to continue their research program for children with disabilities.




GeoVax Reports 2016 Year-End Financial Results

Fri, 24 Mar 2017 14:00:00 EDT

ATLANTA, GA--(Marketwired - Mar 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2016.




NSAV Announces 2.5 Billion Share Reduction

Fri, 24 Mar 2017 10:31:40 EDT

CRESCO, PA--(Marketwired - Mar 24, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 2.5 billion reduction of its authorized shares. The Company took this action after lengthy consultation with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place and that NSAV is not planning or even considering a reverse split of its shares.




Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

Fri, 24 Mar 2017 09:10:00 EDT

CITY OF INDUSTRY, CA--(Marketwired - Mar 24, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in the tumor will be presented at the Endocrine Society Annual Meeting to be held on April 1-4, 2017, at Orange County Convention Center, Orlando, FL. 




The Modernization of eCOA Technology for Clinical Trials, New Webinar Hosted by Xtalks

Fri, 24 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 24, 2017) - During a live session, mobile health solution expert Mike Hughes, Senior Director of eCOA Solutions from YPrime, will provide a timely update on new industry expectations of eCOA technologies. Next generation eCOA platforms have recently evolved to support sophisticated data collection, simplify management from sponsors and sites, and improve patient compliance.




Medigus Announces $7.5 Million Public Offering

Fri, 24 Mar 2017 07:26:11 EDT

OMER, ISRAEL--(Marketwired - Mar 24, 2017) -  Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the pricing of a best efforts public offering of 979,714 Class A Units at a purchase price per unit of $3.50 and of 1,163,144 Class B Units at an effective purchase price per unit of $3.50. Each Class A unit consists of (i) one American Depositary Share, or ADS, and (ii) one Series A warrant to purchase one ADS, and each Class B unit consists of (i) one pre-funded warrant to purchase one ADS, and (ii) one Series A warrant to purchase one ADS. The offering is expected to result in gross proceeds to the company of approximately $7.5 million.




Tiziana Life Sciences PLC: Exercise of Warrants & Issue of Equity

Fri, 24 Mar 2017 05:10:52 EDT

LONDON, UNITED KINGDOM--(Marketwired - Mar 24, 2017) - Tiziana Life Sciences PLC (AIM: TILS)




SNS FiRe Conference Names ElpisEremo a 2017 FiReStarter Company

Thu, 23 Mar 2017 15:13:20 EDT

Global thought leaders converge this October to address some of the world's greatest challenges




AlumiFuel Reports Preliminary Revenue Results for the Fourth Quarter of 2016

Thu, 23 Mar 2017 10:38:02 EDT

CENTENNIAL, CO--(Marketwired - Mar 23, 2017) - AlumiFuel Power Corporation (OTC PINK: AFPW) ("AlumiFuel" or the "Company") today announced preliminary revenue results for the fourth quarter of 2016.




Pressure BioSciences, Inc. Significantly Expands Marketing and Sales Capabilities

Thu, 23 Mar 2017 10:27:22 EDT

Company Engages Highly-Regarded Lead Generation Service and Hires the First Two of Four Field Sales Directors, Executing on its Plan to Aggressively Enhance Product Sales Capabilities in 2017




Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology

Thu, 23 Mar 2017 09:29:00 EDT

Company Provides Update on The Development of Its Pipeline of Non-Invasive Electroceuticals Targeting Vascular Diseases and Ischemia/Reperfusion Injuries




Predictive Technology Group, Inc. (PRED) Announces Development Progress of its Non-Invasive DNA Test for Endometriosis in Three Scientific Presentations

Thu, 23 Mar 2017 09:15:00 EDT

Development of the ARTGuide(R) Test for Endometriosis Test Will Rapidly Accelerate Short and Long-Term Company Growth




PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards

Thu, 23 Mar 2017 09:14:00 EDT

Wins "Top Performer" in all 14 categories




Mount Tam Biotechnologies Announces that the Japan Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

Thu, 23 Mar 2017 09:00:00 EDT

NOVATO, CA--(Marketwired - Mar 23, 2017) -  Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors is pleased to announce that the Japanese Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides composition of matter protection for Mount Tam's lead compound in Japan, complementing Mount Tam's strong intellectual property position in the United States.




Atossa Genetics Opens Enrollment in Study of Endoxifen

Thu, 23 Mar 2017 08:41:12 EDT

SEATTLE, WA--(Marketwired - Mar 23, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has opened enrollment of a Phase 1 study of endoxifen, which is an active metabolite of tamoxifen, an FDA approved drug for breast cancer. The objectives of this placebo-controlled, repeat dose study of 48 healthy female volunteers is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability.




Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification

Thu, 23 Mar 2017 08:00:00 EDT

MISSION VIEJO, CA--(Marketwired - March 23, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)




Upcoming Webinar Assessing NASH: Discover the Non-Invasive Techniques

Thu, 23 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - On Thursday, April 13, 2017, Xtalks will host a complimentary webinar featuring Dr. Richard Ehman, Professor of Radiology, Blanche R. & Richard J. Erlanger Professor of Medical Research, Mayo Clinic; President and CEO, Resoundant, Inc. and Jonathan Riek, Vice President, Musculoskeletal and Metabolic Imaging, BioTelemetry Research (Cardiocore & VirtualScopics) as the presenters.




Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-time, New Webinar Hosted by Xtalks

Thu, 23 Mar 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - Julie Peacock from Client Services at Comprehend and Linda Sullivan, Co-Founder & President of Metrics Champion Consortium (MCC) will provide an in-depth look at CRO oversight and risk management best practice. Their presentation delves into the gaps in oversight processes, the causes of these gaps and how to successfully address them. The live broadcast takes place on Wednesday, April 12, 2017 at 1pm EDT.




Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

Wed, 22 Mar 2017 20:18:32 EDT

Company to Host an Investor Conference Call on Thursday, March 23, 2017 at 10:00 AM EDT




Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update

Wed, 22 Mar 2017 12:34:20 EDT

55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016

New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017

Investor Conference Call Scheduled for Wednesday, March 22, 2017 at 4:30 PM EDT




Science Exchange Named Finalist for Coveted Procurement Leaders World Procurement Awards

Wed, 22 Mar 2017 11:00:00 EDT

Science Exchange on Shortlist for Procurement Service Provider Award; Winners Announced in May




TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology

Wed, 22 Mar 2017 10:00:00 EDT

TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering




Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

Wed, 22 Mar 2017 09:35:26 EDT

HOUSTON, TX--(Marketwired - March 22, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its lead candidate, Annamycin (also known as "Liposomal Annamycin"), an anthracycline, has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).




Advantis Corp. To Introduce New Line of Concentrate-Infused Products, CEO to Be Interviewed on Small Cap Voice

Wed, 22 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 22, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is introducing a new line of premium concentrate-infused products that it will make available through its existing business partners, before kicking off a new marketing campaign. Advantis CEO, Christopher Swartz will comment further on this product line along with providing a future outlook and shareholder update on Small Cap Voice next week.




Pegasystems Launches Pega Service Ventures to Invest in Next Generation Digital Transformation and Customer Engagement Start-ups

Wed, 22 Mar 2017 09:00:00 EDT

Pega's new corporate venture initiative will accelerate growth of the Pega partner ecosystem to help clients achieve exceptional business outcomes




NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 




Sipp Industries Forms Distribution Partnership with Wanderport Corporation to Supply Premium Bulk Hemp Seed and Oil

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - Sipp Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products, is pleased to announce that upon exploration of their complementary synergies, a partnership was established to supply premium bulk hemp seed and oil for Wanderport's (OTC: WDRP) growing selection of consumer hemp based products and premium CBD and hemp coffee line.




American Cannabis Company, Inc. Announces Successful Submission of State Application Materials For All Five Of Its Active Pennsylvania Clients

Wed, 22 Mar 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Mar 22, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced that five of its active clients have successfully submitted application materials and supporting documents for the purpose of acquiring business licenses to operate within the newly founded medical cannabis program that is to be regulated by the State of Pennsylvania.